[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"International Centre for Diarrhoeal Disease Research, Bangladesh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":394},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,82,115,146,181,212,238,260,284,311,344,368],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100634284","phase-2-glucagon-like-peptide-2-glp-2-in-undernourished-women-improving-from-histology-confirmed-environmental-enteric-dysfunction-eed-100634284",false,"NCT07537686","Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)","GAME","Inclusion Criteria:\n\nBangladeshi women, aged 18-35 years\n\n* BMI between 16 kg\u002Fm2 to 18.5 kg\u002Fm2\n* No antibiotics for 1 month\n* Willing to sign the consent form\n* Willing to receive food and multiple micronutrient supplementation for 2 months\n* Willing to receive daily one-month sub-cutaneous GLP 2 analog, Teduglutide treatment\n* Willing to undergo endoscopy and biopsy, twice, before and after intervention, if failed to respond to nutrition intervention and who did not have other chronic or acute diseases that may cause malnutrition\n* Willing to provide biological samples during the study period of 4 months\n\nExclusion Criteria:\n\n* Severe anemia (\\\u003C8 g\u002Fdl), known case of TB, and other chronic diseases, including diabetes mellitus or any congenital disorder or deformity\n* Pregnancy, lactation, drug abuse, known psychiatric disorders\n* High clinical suspicion of cancer or other chronic or acute diseases that may cause malnutrition.\n* Known allergy to any components of nutrition intervention or any GI polyp\n* Ongoing episode of diarrhea, history of persistent diarrhea in the past month or history of acute diarrhea in the past 7 days","FEMALE","18 Years","35 Years",{"count":20,"type":21},55,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn whether teduglutide, a medicine that helps the intestine heal, can improve environmental enteric dysfunction in undernourished women aged 18 to 35 years living in urban slums of Dhaka.\n\nEnvironmental enteric dysfunction is a long-lasting condition of the small intestine. It causes inflammation and poor absorption of nutrients. Many people with this condition do not have clear symptoms, but it can make undernutrition worse. At present, there is no proven treatment for this condition.\n\nThe main questions this study aims to answer are:\n\n* Does taking teduglutide for 30 days improve damage to the small intestine, as seen on intestinal biopsy?\n* Does teduglutide improve blood and stool markers related to gut inflammation and nutrient absorption?\n\nParticipants will:\n\n* Receive nutritional support at the start of the study\n* Undergo an upper gastrointestinal endoscopy to confirm environmental enteric dysfunction\n* Receive a daily injection of teduglutide under the skin for 30 days\n* Undergo repeat endoscopy and laboratory tests after treatment to assess changes in gut health The results of this study will help researchers understand whether teduglutide may be a useful treatment for environmental enteric dysfunction in undernourished adult women and will guide future, larger studies.",[27],"Environmental Enteric Dysfunction",[29,30,31,32,33,34],"Enteropathy","Environmental enteric dysfunction","Teduglutide","Undernutrition","Women","intestinal biopsy","NOT_YET_RECRUITING","2026-04-12",{"date":38,"type":39},"2026-04-17","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2027-12-30",{"name":45,"class":46},"International Centre for Diarrhoeal Disease Research, Bangladesh","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100619483","phase-2-safety-and-immunogenicity-of-id-vs-im-rabies-vaccine-100619483","NCT07345208","Safety and Immunogenicity of ID vs IM Rabies Vaccine","An Open Label, Randomized Non-Inferiority Trial Comparing Safety and Immunogenicity of Intradermal Versus Intramuscular Administration of Registered Rabies Vaccine (by Popular Pharmaceuticals PLC.) in Healthy Bangladeshi Population","Inclusion Criteria:\n\n* Healthy volunteers aged \\>4 years\n* Able to comply with the research process and provide informed consent\n* Able to attend all the scheduled visits and comply with the trial procedures\n* Medical history and clinical examination demonstrating that the subject is healthy\n* Women willing to follow any method of contraception throughout the duration of the study.\n\nExclusion Criteria:\n\n* Subjects participating in other clinical trials in the 4 weeks preceding the first trial vaccination dose\n* Subjects with a history of previous rabies vaccination (either pre- or post-exposure prophylaxis)\n* Subjects with a history of receiving Rabies immunoglobulin (Ig (human\u002Fequine) prior to the study\n* Subjects with a fever (≥37.2°C) or any moderate or severe acute illnesses or active infections on the day of vaccination\n* History of systemic hypersensitivity to any component included in the vaccine or a history of adverse events as a reaction to previous experimental vaccine studies\n* History of receiving any immunoglobulin, blood, or blood-based product in the last 3 months or planning to donate blood in the following 3 months, which may interfere with the immune response\n* Screened as positive for HBsAg, Anti-HCV, and anti-HIV\n* Subjects receiving any vaccine at least 4 weeks prior to enrolment or expected to receive any vaccine 4 weeks after the administration of the trial vaccine.\n* Lactating women or pregnant women as detected by the urine hCG strip test.\n* History of alcohol or any substance abuse (benzodiazepines, methamphetamines, opioids, cannabinoids, cocaine, barbiturates) within 1 year\n* Subjects with congenital or acquired immunodeficiency or subjected to short- or long-term corticosteroid or immunosuppressive therapy\n* Thrombocytopenia, bleeding disorders, or anticoagulants used during the 3 weeks prior to trial vaccination to avoid intramuscular haemorrhage\n* Any major psychiatric disorder such as schizophrenia, major depressive disorder, severe anxiety disorder, etc.\n* History of cardiac arrhythmias, such as bradycardia, tachycardia, supraventricular tachycardia (SVT), ventricular tachycardia (VT), ventricular fibrillation (VF), atrial fibrillation (AF), etc., as assessed by the electrocardiogram report\n* History of renal insufficiency or dialysis\n* Any immunosuppressive disorder, such as cancers, multiple myeloma (MM), various autoimmune diseases, etc.\n* Participants with clinically significant or abnormal laboratory parameters (serum creatinine, SGPT, AST, serum electrolytes) in the opinion of the investigator.\n* Any condition that presents an unacceptable risk of injury, as assessed by the site investigator\n* Subjects planning to have surgery in the 3 months preceding the completion of the project\n* Subjects concurrently using anti-malarial drugs\n* Any condition that, in the researcher's opinion, would jeopardize the safety or rights of the subject or prevent the subject from completing the procedures of the study protocol\n* Subjects exposed to any rabid animal bite in the 4 weeks preceding the commencement of the study.\n* Subjects with Type I or Type II Diabetes, as assessed by Random Blood Sugar level.\n* All research facility staff directly participating in this study, including their immediate family and relatives.",true,"ALL","5 Years",{"count":58,"type":21},90,[24,60],"PHASE3","Background:\n\nBurden: Rabies is a viral zoonotic disease that is 100% fatal if left untreated. Globally, Bangladesh is ranked third in terms of rabies infections. In 2009, the estimated human fatality from rabies in Bangladesh surpassed 2,000. However, the death toll has steadily declined to 26 in 2020, owing to the implementation of the 'National Rabies Elimination Program' beginning in 2010, which included the introduction of the cell culture vaccine. Though this infection is entirely preventable by vaccination, the available intramuscular regimen is costly and requires multiple high doses.\n\nKnowledge gap: The safety and immunogenicity of an intradermal rabies vaccine regimen in the Bangladeshi population needs to be assessed to comply with the recommendation of DGDA to obtain approval to be administered through an alternate route.\n\nRelevance: Intradermal rabies vaccine administration is a safe method that reduces the amount of vaccine needed and the number of doses required by producing immunogenicity similar to that of the intramuscular regimen. This translates to 60-80% cost reductions while preserving the safety and immunogenicity of the vaccine. The intramuscular rabies vaccine by Popular Pharmaceuticals PLC has already been granted marketing authorization by DGDA. However, the vaccine's administration via the intradermal route is yet to receive approval from DGDA for marketing as per the regulatory requirements.\n\nHypothesis: The immunogenicity and safety of the Intradermal rabies vaccine (Popular Pharmaceutical PLC) will be non-inferior to the intramuscular regimen of the same vaccine.\n\nObjectives:\n\n1. To compare the seroconversion level of the intradermal rabies vaccine to the intramuscular regimen by Popular Pharmaceuticals PLC. in healthy Bangladeshi individuals\n2. To compare the safety of the intradermal rabies vaccine to the intramuscular regimen by Popular Pharmaceuticals PLC. in healthy Bangladeshi individuals\n\nMethods: This will be an open-label, non-inferiority, single-blinded, randomized controlled trial where the safety and immunogenicity of the intradermal rabies vaccine will be assessed compared with the standard intramuscular regimen, both by Popular Pharmaceuticals PLC., amongst healthy individuals. The study will be conducted at the Infectious Disease and Tropical Medicine Department (Surya Kanta Hospital), Mymensingh Medical College Hospital, Mymensingh. We will enroll 90 participants and randomly assign them to two equal groups: a test group and a reference group. The test groups will receive 0.2 ml Inj. Rabivax intradermally (0.1 ml in each arm), whereas the reference group will receive 1 ml Injectable Rabivax (2.5 IU\u002Fml) intramuscularly. The participants will be followed up on days 21, 35, and 187 for clinical and biochemical evaluation. A comparative analysis of safety and immunogenicity will be conducted on intradermal and intramuscular administration based on the collected data.\n\nOutcome measures\u002Fvariables:\n\n* A seroconversion level of 0.5 IU\u002Fml or more when tested for Rabies Virus Neutralizing Antibody (RVNA) following intradermal vaccination by Popular Pharmaceuticals PLC. during the study period\n* Non-inferior safety parameters of the intradermal rabies vaccine regimen in comparison with the available intramuscular regimen by Popular Pharmaceuticals PLC.",[63],"Rabies",[65,66,67,68,69,70,71,72],"pre-exposure prophylaxis","intradermal","rabies vaccine","clinical trial","intramuscular","safety","immunogenicity","non-inferiority","2026-01-06",{"date":75,"type":39},"2026-01-15",{"date":77,"type":21},"2025-12-15",{"date":79,"type":21},"2027-07-15",{"name":45,"class":46},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":54,"sex":55,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":81},"100584501","every-newborn-reach-up-early-education-intervention-for-all-children-education-enreach-education-100584501","NCT06890156","Every Newborn Reach Up Early Education Intervention for All Children Education (ENREACH) Education","Bridging Gaps and Scaling Up: a School Readiness Programme for Child-parent-teacher Triad in Bangladesh, Nepal and Tanzania","ENREACH-ED","Inclusion Criteria:\n\n* All children aged 48-84 months\n* Enrolled in preschools\n* Residing in the catchment areas of GPS\n* Include\u002Fover sample for children with functional disabilities even if they are over 84 months of age.\n\nExclusion Criteria:\n\n* Un-consenting parents\n* Intervention school of EN-REACH study","48 Months","84 Months",{"count":93,"type":21},3000,[95],"NA","The goal of the project is to assess the scale-up of the program, focusing on improving school readiness among preschool children, enhancing capacity building for parents and teachers, and utilizing a cluster randomized controlled trial (cRCT). The primary research questions are to seek answer-\n\n* What specific adaptations are necessary for an innovative, disability-inclusive early education training program to become a fully inclusive model that enhances teachers' engagement and practices in pre-primary classrooms in Nepal, Tanzania, and Bangladesh?\n* How can a new, equitable 'School Readiness Programme for the child-parent-teacher triad' be effectively scaled within national government pre-primary platforms using a cRCT?\n* How can the outcomes of the 'School Readiness Programme for the child-parent-teacher triad' be implemented in a cost-effective manner by key stakeholders across the three sites?\n\nThe research will examine an adapted inclusive early education training programme will lead to improved teaching practices, enhanced parental capacity, and better school readiness for all children compared to standard education programme; and b) the child-parent-teacher triad model can be scaled effectively within the government primary education systems.",[98,99],"School Readiness","School Environment",[101,102,103,104,105,106],"School readiness","Early childhood care and education (ECCE)","Early childhood development (ECD)","Pre-primary education","disabilities","Cluster randomized controlled trial (cRCT)","2025-06-22",{"date":109,"type":39},"2025-06-26",{"date":111,"type":21},"2025-07",{"date":113,"type":21},"2027-03",{"name":45,"class":46},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":132,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":81},"100505513","the-maternal-eed-study-100505513","NCT05862363","The Maternal EED Study","Small Intestinal Microbiota of Low Body Mass Index (BMI) & Normal BMI Women of Reproductive Age and Microbiota-directed Balanced Energy Protein (MD-BEP) Supplementation in Maternal Environmental Enteric Dysfunction (EED)","Inclusion Criteria:\n\nInclusion criteria for pregnant low-BMI women\n\n1. Bangladeshi female, age 18-35 years\n2. BMI 20-24.9 kg\u002Fm2\n3. Middle-upper socioeconomic class (≥ $11\u002Fday family income)\n4. Functional dyspepsia\n5. Willing to sign the consent form\n6. Willing to provide biological samples during the study period of 6 months\n\nInclusion criteria for non-pregnant low-BMI women 1. Bangladeshi female, age 18-35 years\n\n1. BMI \\\u003C18.5 kg\u002Fm2\n2. No antibiotics for 1 month\n3. Willing to sign the consent form\n4. Willing to undergo endoscopy and biopsy\n5. Willing to provide biological samples during the study period of 6 months\n6. Willing to receive food supplementation for 3 months\n\nInclusion criteria for normal-BMI non-pregnant women\n\n1. Bangladeshi female, age 18-35 years\n2. BMI 20-24.9 kg\u002Fm2\n3. Middle-upper socioeconomic class (≥ $11\u002Fday family income)\n4. Functional dyspepsia\n5. Willing to sign the consent form\n6. Willing to provide biological samples during the study period of 6 months\n\nInclusion criteria for normal-BMI pregnant women\n\n1. Bangladeshi female, age 18-35 years\n2. BMI 20-24.9 kg\u002Fm2\n3. Middle-upper socio-economic class (≥ $11\u002Fday family income)\n4. Enrolled at the end of first-trimester of pregnancy (before 14 weeks of gestation)\n5. Willing to sign the consent form\n6. Willing to undergo endoscopy and biopsy\n7. Willing to provide biological samples during the study period\n8. Willing to let anthropometry and biological sample collection from her newborn for the first 6 months of life\n\nExclusion Criteria:\n\nExclusion criteria for pregnant low-BMI women\n\n1. Received antibiotics during the last one month\n2. Presence of any chronic disease including diabetes mellitus or any congenital disorder or deformity\n3. Ongoing episode of diarrhea, history of persistent diarrhea in the past month or history of acute diarrhea in the past 7 days\n\nExclusion criteria for non-pregnant low-BMI women\n\n1. Severe anemia (\\\u003C8 g\u002Fdl), TB and other chronic diseases, including diabetes mellitus, urogenital infections or any congenital disorder or deformity\n2. Pregnancy, lactation, drug abuse, known psychiatric disorders\n3. High clinical suspicion of cancer or other chronic or acute diseases that may cause malnutrition. Adult participants who fulfill the inclusion criteria and are not excluded through history and clinical examination will undergo following screening tests based on clinical judgement:\n\n   1. Chest x-ray\n   2. Urine for R\u002FE\n   3. Ultrasonography of whole abdomen\n   4. Fasting blood glucose\u002F HbA1c\n   5. Stool for OBT (occult blood test)\n   6. Cancer markers (ie. CEA, CA 15.3, CA 19.9)\n4. Known allergy to any components of nutrition intervention\n5. Nugent Score\u002FAmsel Criteria to exclude bacterial vaginosis: A Nugent score 3-4 is consistent with Bacterial vaginosis (BV). The modified Amsel criteria with a cut-off value of 2 (pH+VD; sensitivity 71%, specificity 90%, accuracy 88% or KOH+VD; sensitivity 75%, specificity 91%, accuracy 89%) might be considered for this purpose20.\n6. Ongoing episode of diarrhea, history of persistent diarrhea in the past month or history of acute diarrhea in the past 7 days\n\nExclusion criteria for non-pregnant normal-BMI women\n\n1. Received antibiotics during the last one month\n2. Presence of any chronic disease including diabetes mellitus or any congenital disorder or deformity\n3. Ongoing episode of diarrhea, history of persistent diarrhea in the past month or history of acute diarrhea in the past 7 days\n\nExclusion criteria for pregnant normal-BMI women\n\n1. Multiple pregnancy (carrying two or more fetuses)\n2. Threatened abortion, persistent pervaginal bleeding, or cervical incompetence\n3. History of three or more consecutive abortions\n4. History of gestational diabetes, macrosomia, gestational hypertension, preeclampsia\u002Feclampsia in a prior pregnancy\n5. Active disease\u002Fcomplications requiring acute phase treatment in a hospital\n6. Tuberculosis\n7. Severe anemia (Hb concentration \\\u003C 8 mg\u002Fdl)\n8. Antibiotic use (ongoing or within last two weeks before the onset of intervention)\n9. Taking medications such as insulin, thyroid hormones, glucocorticoids\n10. Chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy, or any congenital disorder or other diseases which could impede compliance with the study protocol\n11. Known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder\n12. Having known history of allergy to the therapeutic agents\n13. Having a plan to move or deliver outside the study area\n14. Known allergy to any components of nutrition intervention.",{"count":123,"type":21},180,[95],"Undernutrition among women of reproductive age is more common in South Asia than in any other region. In South Asia, the prevalence of maternal undernutrition varies between 10 and 40%. There is a scarcity of data on the contribution of small intestinal (SI) microbiota to pathogenesis of Environmental Enteric Dysfunction (EED) of malnutrition, as it is difficult to obtain gut biopsy specimens from malnourished individuals, especially children. The Bangladesh Environmental Enteric Dysfunction (BEED) study, involving participants who live in an urban slum (Mirpur) in Dhaka, provided an opportunity to examine the role of the duodenal microbiota in the pathogenesis of EED in children and also performed esophagogastroduodenoscopy (EGD) on thirty-eight 18-45-year-old malnourished (BMI\\\u003C18.5 kg\u002Fm2) women residing in the same resource-poor setting of Mirpur, Dhaka who failed to respond to an egg\u002Fmilk\u002Fmicronutrients- based nutritional intervention comparable to that given to children. In this intervention component, beginning at the end of the first trimester, low-BMI (\\\u003C18.5 kg\u002Fm2) pregnant women (aged 18-35 years) will be randomly assigned to receive either Microbiota-directed Balanced Energy Protein (MD-BEP) or Ready-to-Use-Supplementary Food Balanced Energy Protein (RUSF-BEP) for the duration of their pregnancy and during the first 3 postnatal months, in addition to standard antenatal care. A parallel cohort of age-matched normal-BMI pregnant women who will not receive any nutritional intervention will serve as a reference control group.",[127,128,129,130,131],"Environmental Enteric Dysfunction (EED)","Malnutrition","Women of Reproductive Age","Gut Microbiota","Balanced Energy Protein (BEP)",[133,134,135,128,136],"Balanced energy protein (BEP)","Environmental enteric dysfunction (EED)","Gut microbiota","Women of reproductive age","RECRUITING","2025-05-12",{"date":140,"type":39},"2025-05-14",{"date":142,"type":39},"2023-01-02",{"date":144,"type":21},"2026-12-31",{"name":45,"class":46},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":55,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":165,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":81},"100420079","phase-3-management-of-shock-in-children-with-sam-or-severe-underweight-and-diarrhea-100420079","NCT04750070","Management of Shock in Children With SAM or Severe Underweight and Diarrhea","Randomized Controlled Trial of Dopamine, Adrenaline, and Blood Transfusion for Treatment of Fluid Refractory Shock in Children With Severe Acute Malnutrition or Severe Underweight and Cholera or Other Dehydrating Diarrheas","Inclusion Criteria:\n\n1. Children of either sex with acute malnutrition and diarrhea\n2. Age: 1-59 months\n3. Children with cerebral palsy (CP) and\u002For developmental delay, Down Syndrome with or without heart diseases\n4. Fluid refractory shock\n5. Consent from the caregivers\u002Fparents\n\nExclusion Criteria:\n\n1. Having a rare blood group (Rh negative blood groups provided that donor is not available)\n2. A child requiring cardio-pulmonary resuscitation during screening or having gasping respiration","1 Month","59 Months",{"count":156,"type":21},135,[60],"Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths. The coexistence of sepsis and hypovolemic shock in children with severe acute malnutrition (SAM) having diarrhea is common. At Dhaka hospital of icddr,b, the death rate is as high as 40% and 69% in children with severe sepsis and septic shock respectively with co-morbidities such as severe malnutrition.\n\nThe conventional management of SAM children with features of severe sepsis recommended by WHO includes administration of boluses of isotonic saline followed by blood transfusion in unresponsive cases with septic shock; whereas the Surviving Sepsis Campaign (SSC) guideline recommends vasoactive support. To date, no study has evaluated systematically the effects of inotrope(s) and vasopressor or blood transfusion in children with dehydrating diarrhea (for example, in cholera) and SAM having shock and unresponsive to WHO standard fluid therapy.\n\nThis randomized trial will generate evidence whether inotrope and vasopressor or blood transfusion should be selected for severely malnourished children having hypotensive shock and who failed to respond to WHO standard fluid bolus.",[160,161,162,163,164],"Shock Hypovolemic","Shock, Septic","Blood Transfusion","Adrenaline","Dopamine",[166,167,168,169,170,171,172],"Severe acute malnutrition","Children","Shock","Cholera","Dehydrating diarrhea","Severe underweight","Acute malnutrition","2025-04-13",{"date":175,"type":39},"2025-04-16",{"date":177,"type":39},"2021-08-17",{"date":179,"type":21},"2025-11-30",{"name":45,"class":46},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":54,"sex":55,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":81},"100578787","phase-3-non-interference-study-of-mr-and-yellow-fever-vaccines-among-bangladeshi-infants-aged-9-12-months-100578787","NCT06815835","Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","A Prospective, Randomized, Parallel, Three-arm, Open-label, Clinical Trial to Evaluate the Immunological Non-interference of Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) of M\u002Fs. Zydus Lifesciences Ltd. With Yellow Fever Vaccine Administered to Bangladeshi Healthy Infants Aged 9-12 Months","Inclusion Criteria:\n\n* The participant must satisfy all the following criteria to be eligible for enrolment:\n* Healthy infant participants of either gender aged\\* 9 to 12 months at the time of enrollment\n* Participants should be in good health as determined by the medical history and physical examination based on the clinical judgment of the investigator\n* No previous history of vaccination against measles, rubella, or Yellow fever\n* Written informed consent from the participant's parent\u002Fguardian\n* Participant's parent\u002Fguardian literate enough to fill the diary card \\*Age calculated as per completed month\n\nExclusion Criteria:\n\n* Participants positive for serological markers against Dengue and\u002For Japanese Encephalitis infections\n* History of hypersensitivity reaction to any component of the study vaccines including egg and chicken proteins\n* History of hypersensitivity reaction to neomycin\n* History of laboratory-confirmed or suspected measles, rubella, or Yellow fever in the past\n* Participant exposed# to measles, rubella, or Yellow fever virus within the past 30 days\n* Fever of any origin or infectious disorder of 3 days or more within the past month\n* Febrile illness (axillary temperature ≥37.5°C) at the time of enrollment\n* History of any vaccination within the past month\n* Clinically significant systemic disorders such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological, immunological, or metabolic disorder\n* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or participants on any immunosuppressive or immunostimulant therapy\n* Known case of thrombocytopenia or any coagulation disorder, or participants on anticoagulation therapy\n* Participants administered blood, blood-containing products, or immunoglobulins within the last 3 months or planned administration during the study\n* Participant participated in another clinical study in the past 3 months\n* Any other reason for which the investigator feels that the participant should not participate #Close contact (family member or neighbour) with laboratory-confirmed or clinical diagnosis of measles\u002Frubella\u002FYellow fever","9 Months","12 Months",{"count":191,"type":21},1530,[60],"This study will be conducted among 1530 healthy infants of 9 to 12 months of age residing in the Dakshinkhan and Uttarkhan area which is located in Dhaka North City Corporation (DNCC) to enroll the required number of participants. Only infants who have not previously received the MR and YF vaccines will be enrolled. The findings of this study are likely to have a significant impact on vaccine co-administration strategies for campaign and routine immunization programs. The participants will be assigned to one of the three groups by the central computer-generated randomization schedule. The numbers are defined for each arm (Table 1) based on the sample size calculation. A list of infants who did not receive MR and Yellow fever vaccine will be prepared before enrollment by trained study staff (TSS). The TSSs will visit households in the defined study area and ask if the parents\u002Fguardians of infants aged 9-12 months are willing to participate in the study. If they show a willingness to participate, the TSSs will check their vaccination cards (if available) and prepare the list of potentially eligible infants who have not received MR and Yellow fever vaccines based on their vaccination card status. The investigators will collect blood specimens (4-5 ml) at the time of screening (visit-1), to evaluate serological markers of dengue and Japanese Encephalitis infection and for baseline (pre-vaccination) immunological assessment. The investigators will vaccinate seronegative, eligible participants within 24 hours of blood collection. There will be additional three follow-up visits after enrollment and will collect around 3-4 ml blood from each participant during visit 4 (week 6), and visit 5 (week 26) for immunological assessment. Diary cards will be used to collect adverse events (AEs) following immunization (AEFI) data for vaccinated participants (up to 14 days for solicited and 6 weeks for unsolicited AEs). Medically attended adverse events (MAAEs) and data on serious adverse events (SAEs) will be reported during the study. All study updates including AEs and SAEs will be reported to the data safety and monitoring board (DSMB) and sponsor.",[195,196,197],"Measles","Rubella","Yellow Fever",[199,200,201,202,203],"Safety","Non-interference","Measles and Rubella","Co-administration","Immunogenicity","2025-02-06",{"date":206,"type":39},"2025-02-07",{"date":208,"type":21},"2025-04-01",{"date":210,"type":21},"2026-03-31",{"name":45,"class":46},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":54,"sex":55,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":235,"leadSponsor":237,"locationsCount":81},"100574284","phase-3-zyvac-tcv-bangladesh-study-100574284","NCT06757283","ZyVac-TCV Bangladesh Study","Evaluation of Typhoid Conjugate Vaccine (TCV) Effectiveness Among Bangladeshi Children Using the Test-negative Design","Inclusion Criteria:\n\n* Participant was included in the baseline list of the study population\n* Participants living within the study catchment area at the time of vaccination\n* Parent\u002Fguardian is willing and competent to provide informed consent (if the participant is 11 to 15 years of age, assent will also be sought)\n* Participants aged between 6 months to15 years (i.e. up to 15 years 364 days) at the time of vaccination\n* Apparently healthy (no complaints of febrile illness) on the day of vaccination\n* Parent\u002Fguardian confirms that their child will be willing and be able to comply with study requirements\n\nExclusion Criteria:\n\n* Has knowingly received a typhoid vaccine in the past\n* Known allergy to any vaccine in the past\n* Medical or social reasons that will prevent the participant from conforming to the study requirements as judged by a medical professional\n* Planning to move away from the catchment area within the next 12 months\n* Pregnant at the time of vaccination, as confirmed by a urine test (urine pregnancy test will be done in girls who are married)\n* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or subjects on any immunosuppressive or immunostimulant therapy\n* Subject participated in another clinical study in the past 3 months","6 Months","15 Years",{"count":222,"type":21},4000,[60],"This is a prospective closed cohort, open-label, phase III effectiveness study using a test-negative design of a typhoid conjugate vaccine, ZyVac® TCV (purified Vi capsular polysaccharide of Salmonella Typhi conjugated to tetanus toxoid as carrier protein), manufactured by Zydus Lifesciences Limited. The study will be conducted in a closed cohort population among children aged 6 months to 15 years residing in wards 5, 6, 7, 48, 49, 50, 63, 71, and 72 of Dhaka South City Corporation (DSCC). The targeted number of age-eligible children in the study area is \\~92,000 among them \\~60,000 will be vaccinated. A subset of the first 600 consenting participants will be selected by age strata (6 months to \\\u003C2 years, 2-4 years, 5-15 years) for enrollment in the immunogenicity study with an additional three follow-up visits. Diary cards will be used to collect adverse events (AEs) following immunization (AEFI) data up to day 7 for a subset of active follow-up of the first 600 vaccinated participants. Participants not in this subset will be encouraged to go to the 'Adverse Event Monitoring Cell' at the Maniknagar field office. Data on serious adverse events (SAEs) will be reported for six months after vaccination. All study updates including AEs and SAEs will be reported to the data safety and monitoring board (DSMB) and sponsor. Passive surveillance for typhoid fever will be carried out in the Maniknagar field office and Mugda Medical College and Hospital in the catchment area among the age-eligible children.",[226,227,228],"Typhoid Vaccination","Typhoid","Typhoid Fever",[230,203,199,231,232,167],"Conjugate vaccine","Typhoid fever","Bangladesh",{"date":206,"type":39},{"date":208,"type":21},{"date":236,"type":21},"2026-05-30",{"name":45,"class":46},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":54,"sex":55,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":4},"100573617","phase-4-immunogenicity-of-different-primary-immunization-schedules-with-inactivated-poliovirus-vaccine-ipv-plus-pentavalent-vaccine-dtwp-hbv-hib-or-with-hexavalent-vaccine-dtwp-hbv-hib-ipv-100573617","NCT06748612","Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","A. Assessment of seroprotection and safety of wP-Hexa with primary immunization schedules.\n\nInclusion Criteria:\n\n1. Healthy infants 6 weeks of age (range: 42-48 days).\n2. Parents that consent for participation in the full length of the study.\n3. Parents that can understand and comply with planned study procedures.\n\nExclusion Criteria:\n\n1. Parents and infants are unable to participate in the full length of the study (e.g., plan to move away from the study area during the study period).\n2. A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.\n3. A diagnosis or suspicion of bleeding disorder that would contraindicate administration of IPV, wP Penta or wP-Hexa, or collection of blood by venepuncture.\n4. Acute diarrhoea, infection, or illness at the time of first study vaccination that would require infant's admission to a hospital.\n5. Acute vomiting and intolerance to liquids within 24 hours before the first study vaccination.\n6. Any encephalopathy of unknown origin occurring within 7 days following previous vaccination with any pertussis containing vaccine.\n7. Uncontrolled neurologic disorder or uncontrolled epilepsy (Pertussis vaccine should not be administered to individuals with these conditions until the treatment regimen has been established and the condition has stabilized).\n8. Evidence of a chronic medical condition identified by a study medical officer during physical exam.\n9. Receipt of any polio vaccine (OPV or IPV) before enrolment based upon documentation or parental recall.\n10. Known allergy\u002Fsensitivity or reaction to polio, pertussis, tetanus, diphtheria, hepatitis B, Hib vaccines or its contents.\n11. Infants from multiple births. This exclusion is done because the non-participant infant will likely receive OPV through routine immunization and may transmit vaccine poliovirus to the enrolled infant.\n12. Infants from premature births (\\\u003C37 weeks of gestation).\n\nB. Mucosal immunity against poliovirus sub-study :\n\nInclusion criteria\n\n* Participants:\n\n  * Participants in study arms A and B who complete study procedures up to 18 months and whose parents do not request discontinuation\n* Controls:\n\n  * Children aged 18 months who have received polio vaccination through routine immunization services verified by immunization card (bOPV at 6, 10 and 14 weeks; fIPV at 6 and 14 weeks)\n\nExclusion criteria\n\n1. Parents and infants are unable to participate in the full length of the study (e.g., plan to move away from the study area during the study period).\n2. A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.\n3. A diagnosis or suspicion of bleeding disorder that would contraindicate administration of bOPV or collection of blood by venepuncture.\n4. Acute diarrhoea, infection, or illness at the time of enrolment (18 months of age) that would require infant's admission to a hospital.\n5. Febrile disease that contraindicates administration of pentavalent vaccine (even if hospitalization is not required).\n6. Acute vomiting and intolerance to liquids within 24 hours before the enrolment visit (18 months of age).\n7. Known allergy\u002Fsensitivity or reaction to oral polio vaccines or its contents.\n8. Received any polio vaccines outside of the routine immunization schedule.\n9. Household members have received OPV within 1-2 months prior to enrolment.","42 Days","48 Days",{"count":247,"type":21},1190,[249],"PHASE4","The goal of this study is to provide information on immunogenicity at short and medium term for hexavalent with different schedules, which will be useful for the global polio program and countries, including Bangladesh.\n\nPrimary objectives are\n\n1. To compare the proportion of participants who seroconvert to all poliovirus serotypes four weeks after a primary immunization series.\n2. To compare the proportion of participants seropositive against all poliovirus serotypes at 18 months of age.\n\nThis is an open-label randomized clinical trial. Participants will be enrolled and randomized at 6 weeks of age to one of three arms. Target enrolment is 330 infants per arm and 200 controls; 990 in the main study and \\~ 800 in the sub-study.\n\nA total of 4-5 blood samples will be collected from each infant before and after the primary vaccination series, and at 18 months of age, to assess systemic immune response to different antigens.\n\nOutcome measures\u002Fvariables:\n\nNeutralizing antibody titers in serum will be quantified for poliovirus types 1, 2, and 3 using a microneutralization test; for diphtheria toxoid, tetanus toxoid, and pertussis toxin using a Multiplex bead assay; and for antibodies to hepatitis B surface antigen (anti-HBs) using serologic assay. The presence of poliovirus types 1 and 3 in oropharyngeal swabs and stools following the bOPV challenge will be tested using a real-time reverse transcription PCR (rRT-PCR) assay.",[252],"Polio","2024-12-21",{"date":255,"type":39},"2024-12-27",{"date":257,"type":21},"2025-01-28",{"date":43,"type":21},{"name":45,"class":46},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":54,"sex":55,"minAge":266,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":81},"100463187","nutri-cap-nutrition-for-children-adolescent-girls-and-pregnant-women-in-slums-of-dhaka-city-100463187","NCT05311436","Nutri-CAP: Nutrition for Children, Adolescent Girls, and Pregnant Women in Slums of Dhaka City","Inclusion Criteria:\n\n* Pregnant women:\n\n  * Age 18-39 years\n  * Before 16 weeks of gestation\n  * BMI 15-24.99 kg\u002Fm2 measured on enrolment\n  * Have the plan to stay in the study area till delivery\n  * Willing to participate in the study\n  * Not enrolled in any nutrition project\u002Fprogramme currently\n\nAdolescent girls:\n\n* Aged 11-19 years\n* Willing to participate in the study\n* Not involved in any nutrition project\u002Fprogramme\n* Will stay in the study area for the next 2 years\n\nChildren:\n\n* Aged 0-24 months\n* Youngest child of the household\n* Caregivers have the plan to stay in the study area at least up to two years of age\n* Not enrolled in any nutrition project\u002Fprogramme currently\n\nExclusion Criteria:\n\n* Pregnant women:\n\n  * Subject not willing to provide consent\n  * Subject has the plan to migrate outside of the study area during the study period\n  * Subject has a plan to go elsewhere ( village\u002F parents' house) for delivery\n  * Any reported\u002Fdiagnosed chronic diseases (such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy, or any other diseases which could impede compliance with the study protocol)\n  * Extremely obese\n  * Subject involved in any nutrition programme\u002F intervention currently\n\nAdolescent girls:\n\n* Subject not willing to give assent\u002Fconsent\n* Subject has the plan to migrate outside the study area during the study period\n* Subject involved in any nutrition programme\u002Fintervention currently\n\nChildren:\n\n* Caregiver\u002Fguardian not willing to provide consent\n* Have the plan to migrate outside of the study area during the study period\n* Child with any congenital anomaly\n* Subject involved in any nutrition programme\u002Fintervention currently","1 Day","39 Years",{"count":269,"type":21},3278,[95],"The objective of the research project is to establish an evidence-based sustainable nutrition service delivery platform for optimizing pregnancy weight gain, increasing dietary diversity of adolescent girls, and ensuring proper physical growth of under 2 children.\n\nHypothesis\n\n1. Pregnant Women: Intensive nutrition and WASH counseling, iron-folate, calcium supplementation during pregnancy, can improve gestational weight gain and improve hemoglobin status in pregnant women in a slum of Dhaka city\n2. Adolescent girl: Iron and zinc supplementation and nutrition counseling on dietary diversity could improve nutritional status and dietary diversity score in adolescent girls of slums in Dhaka\n3. Children \\\u003C2 years: Counselling on IYCF, growth monitoring, and promotion, ensuring six-monthly vitamin A supplementation, counseling on WASH, treatment of acute malnutrition, and daily 1 egg supplementation for 3 months for severely stunted children can improve the nutritional status of children\n4. Counselling to improve Water, Sanitation and Hygiene (WASH) practice: WASH intervention can improve EED biomarkers",[273,274,32,275],"Gestational Weight Gain","Diet, Food, and Nutrition","Health Behavior","2024-10-27",{"date":278,"type":39},"2024-10-30",{"date":280,"type":39},"2022-04-01",{"date":282,"type":21},"2024-12-31",{"name":45,"class":46},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":55,"minAge":219,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100556851","post-discharge-trial-to-enhance-immunity-in-severely-malnourished-children-100556851","NCT06530485","Post Discharge Trial to Enhance Immunity in Severely Malnourished Children","Enhancing Immunity and Nutrition in Severely Malnourished Children Following Hospital Discharge: a Two Arm Open-label Randomized Controlled Trial of Microbiota-Directed Food vs. Zinc With Micronutrient Powder and Khichuri","Inclusion Criteria:\n\n* Children aged 6 months to 36 months, and\n* Severe acute malnutrition as evident by weight-for-length z-score (WLZ) \\\u003C -3 and or mid-upper arm circumference (MUAC) \\\u003C 11.5 cm, and or edema of both feet, and\n* Completed the acute phase management for SAM and stayed at NRU for 7±4 days, with no medical complications, e.g. lethargic\u002Funconscious, convulsions, unable to drink, persistent vomiting, respiratory distress.\n* Residing within the Dhaka district.\n* Parents\u002Fguardians provided written informed consent.\n\nExclusion Criteria:\n\n* WLZ ≥ -3 or MUAC ≥11.5 cm.\n* Presence of lethargy\u002Funconsciousness, convulsions, unable to drink, persistent vomiting, respiratory distress.\n* Participants who receive multiple courses of antibiotic (\\>2 courses during acute phase) treatment for a prolonged period (\\>14 days).\n* Persistent diarrhea (≥14 days).\n* Chronic illness or disability affecting food intake, e.g. TB, HIV, congenital defects, cerebral palsy\n* Treated for SAM in the previous 3 months.\n* Known case of soy, peanut, or milk protein allergy.\n* Any sibling of the enrolled child.","36 Months",{"count":293,"type":21},150,[95],"The goal of this study is to evaluate the efficacy of microbiota-directed food in comparison to zinc with micronutrient powder and Khichuri on changes in circulating immune cells (monocytes, T cells, B cells, and NK cells) in malnourished children after recovery from acute infection.\n\nThe study aims to answer the research question:\n\nDoes microbiota-directed food (MDF) compared to zinc with micronutrient powder (MNP) and Khichuri therapy enhance immunity in children with severe acute malnutrition? The researcher will compare the effectiveness of microbiota-directed food (MDF) versus zinc with micronutrient powder (MNP) and Khichuri therapy to see if MDF enhances immunity in severely malnourished children.\n\nSeverely malnourished children will:\n\n* Receive microbiota-directed food (MDF) or zinc with micronutrient powder (MNP) and Khichuri every day for 12 weeks.\n* Phenotyping of circulating immune cells (NK cells, T cells, B cells) will be conducted using flow cytometry and fluorescence-activated cell sorting techniques.",[297],"Child Malnutrition",[299,128,300,301,302,135],"Immunity","Microbiota-directed food (MDF)","Zinc","NK cells","2024-07-31",{"date":305,"type":39},"2024-08-02",{"date":307,"type":21},"2024-08-01",{"date":309,"type":21},"2025-12-31",{"name":45,"class":46},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":54,"sex":16,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":330,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":81},"100483093","12--bangladesh-center-for-global-environmental-and-occupational-health--bangladesh-100483093","NCT05570552","1\u002F2- Bangladesh Center for Global Environmental and Occupational Health- Bangladesh","Long Term Effects of Household Air Pollution (HAP) Reduction on Cardio-pulmonary and Immune Function Outcomes - a Household Level Randomized mHealth Intervention Trial","GEOHealth-II","Inclusion Criteria:\n\n* Participants in the previous GEOHEALTH round-I study\n* Aged between 25 and 70 years\n* Live in biomass-using home with traditional stoves\n* Non-smoker and live with non-smokers\n* Exposed to \\\u003C10 µg\u002FL of water arsenic\n\nExclusion Criteria:\n\n* Known to have immune related illness or taking any prescription medication (particularly those that suppress or enhance immune function)\n* Known to have any clinical events of CVD or lung disease, including stroke or coronary heart disease.","25 Years","70 Years",{"count":322,"type":21},1000,[95],"Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass (wood, agricultural residue, cow dung, etc.) fuel use for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use, especially in low- and middle-income countries (LMICs). Earlier the investigators showed that Liquid Petroleum Gas (LPG) for 24 months, reduced personal PM2.5 exposure by 58.17 percent which induced novel changes in immune and inflammatory responses in the participants; however cardiopulmonary markers remained relatively stable in post-intervention assessment.\n\nIn this study, the investigators aim to evaluate the effects of mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention on adoption and exclusive use of LPG. The investigators also aimed to observe whether long-term effects of HAP reduction can impact the subclinical measures of cardio-vascular and pulmonary dysfunction and regulate innate and inflammatory immune function among women and children in semi-rural settings in Bangladesh. The investigators will also investigate the influence of exposure to HAP on antibody response to vaccines (adaptive immunity). The BCC intervention will be provided by conducting a large household level randomized controlled trial by educational intervention using mHealth based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine.",[326,327,328,329],"Air Pollution","mHealth Intervention","Cardiopulmonary Function","Immune Function",[331,332,333,334,335],"Mobile based Behavioral Change Communication intervention","Household air pollution reduction","Cardiopulmonary function","Immune function","Clean fuel LPG","2024-03-20",{"date":338,"type":39},"2024-03-22",{"date":340,"type":39},"2023-06-20",{"date":342,"type":21},"2027-06",{"name":45,"class":46},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":55,"minAge":219,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":81},"100539823","microbiota-directed-food-for-children-with-severe-acute-malnutrition-100539823","NCT06308848","Microbiota Directed Food for Children With Severe Acute Malnutrition","Proof-of-Concept Study for a Microbiota-Directed Food in Children With Uncomplicated Severe Acute Malnutrition in Rural Bangladesh","Inclusion Criteria:\n\n* The trial will include SAM children of either sex without any medical complication\n* Children aged between 6-\\\u003C24 months and with MUAC \\\u003C115 mm and\u002For WLZ \\\u003C-3\n\nExclusion Criteria:\n\n* Children are not suffering from SAM.\n* Children with bi-pedal oedema.\n* Failed to obtain consent for study participation from parents or legal guardian.\n* Suffering from any chronic illness(es) or having severe anemia (\\\u003C 8 g\u002Fdl).\n* History of using antibiotics in the past seven days.\n* Children participating in other food intervention programs.\n* Children having known history of soy, peanut or milk protein allergy.\n* Children who will not pass appetite test.","24 Months",{"count":353,"type":21},256,[95],"Severe acute malnutrition (SAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing SAM is crucial to prevent its progression to other childhood morbidity and mortality and to ensure healthy child development. To meet the nutritional requirement of SAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use therapeutic food. The investigators propose this proof-of-concept trial to establish evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with SAM in comparison to the standard RUTF.",[357],"Severe Acute Malnutrition",[359,360,135,232],"Microbiota directed food","SAM","2024-03-11",{"date":363,"type":39},"2024-03-13",{"date":365,"type":21},"2024-04-15",{"date":144,"type":21},{"name":45,"class":46},{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":55,"minAge":375,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":378,"phases":4,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":81},"100524024","fungal-surveillance-in-bangladesh-100524024","NCT06103331","Fungal Surveillance in Bangladesh","Surveillance for Invasive Fungal Infections in Selected Hospitals in Dhaka City, Bangladesh","Inclusion Criteria:\n\n* Inclusion criteria:\n\nMust include all of the following criteria:\n\n1. Admitted\u002Fhospitalized patients of any age and gender in tertiary-level acute care hospitals AND\n2. Having any of the following co-morbid immunosuppressive conditions or risk factors for healthcare-associated fungal infections such as:\n\n   * Chronic lung conditions including asthma, COPD\n   * Hemodialysis patients,\n   * diabetes,\n   * Patients receiving chemotherapy or immunosuppressive drugs (e.g. corticosteroids, immunosuppressive drugs among organ transplant recipients), for ≥7 days\n   * Patients with AIDS\n   * Patients at risk of healthcare-associated infections (e.g., Patients under postoperative care, having a urinary catheter, with tracheal intubation, under ventilatory support, secured with intravenous (IV) cannula, any other invasive procedures, etc.)\n   * Hospitalized Patients under prolonged injectable antibiotic treatment (\\>7 days)\n   * Prolonged hospitalization more than 7 days.\n   * History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization\n\n   AND\n3. Patients or caregivers providing consent\n\nFor children aged \\\u003C5 years, the age criteria and additional inclusion criteria will be as follows:\n\n* 0 to 59-month-old children of either sex admitted in hospital with any illness.\n* Have features of sepsis\u002Fpneumonia (based on clinical features below)\n\nAnd any of the following criteria:\n\n* Those who will fail to respond to injectable antibiotics or both 1st and 2nd line antibiotics (1st line- inj. Ampicillin plus gentamicin, 2nd line- inj. Ceftriaxone plus levofloxacin\u002Fgentamicin as per icddr,b hospital protocol)\n* Any child with SAM or h\u002Fo recent measles or any condition that may induce immune suppression plus fail to respond to injectable antibiotics\u002F 1st line antibiotics (1st line antibiotics- inj. Ampicillin +inj. Gentamicin)\n* Those who will develop late-onset hospital-associated infection (LOHAI)\n* Any child who will require ICU care for more than 7 days\n* Develop extensive thrush after taking long-term injectable antibiotics\n* History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization\n\nExclusion Criteria:\n\n* History of taking antifungal drugs within 2 weeks\n* Not willing to give consent","0 Months",{"count":377,"type":21},800,"OBSERVATIONAL","This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals. including the Dhaka Medical College Hospital, the Dhaka Hospital of icddr,b, and the National Institute of Cancer Research Hospital (NICRH). Respiratory samples, blood, urine, cerebrospinal fluid, surgical wound infection swabs, and other samples including biopsy tissue specimens will be obtained at intensive care units, general medicine and surgery wards, post-operative care, etc. The collected specimens will be sent to the clinical microbiology laboratories of the surveillance hospitals or to the pathology laboratory (biopsy tissue specimens) to test for Aspergillus, Histoplasms, Candida, Pneumocystis, Cryptococcus, and Mucormycetes. The lab. methods will include microscopy, staining, culture, and biochemical tests mainly and if feasible then some specimens may undergo molecular or immunological methods.",[381],"Invasive Fungal Infections",[383,384,385],"Invasive Fungal Pathogen","Hospitalized patients","Surveillance","2023-11-20",{"date":388,"type":39},"2023-11-22",{"date":390,"type":39},"2022-01-20",{"date":392,"type":21},"2026-09-30",{"name":45,"class":46},""]